RSU Tax Planning for Medtech Executives

Restricted stock units are not taxed when they are granted. Because a grant is only a promise of shares on a future date, there is nothing of realized value to tax yet, and no tax is owed at that point.

The taxable event happens at vesting. When RSUs vest, the fair market value of the shares on that vesting date is treated as ordinary income and added to your W-2 wages for the year, regardless of whether you sell the shares or continue holding them. That value is also generally subject to Social Security and Medicare withholding, the same as a paycheck.

Vesting and selling are two separate events for tax purposes. Vesting sets your ordinary income and establishes your cost basis in the shares. Selling later, at a higher or lower price than the vesting-date value, creates a separate short-term or long-term capital gain or loss, measured from that basis rather than from zero.

At vesting, there are generally two paths for the shares that land in your account. Sell-to-cover means selling enough of the newly vested shares immediately to cover the associated tax withholding, and keeping the rest. Holding means keeping all of the vested shares and covering any taxes from other funds if needed.

Each approach carries trade-offs rather than a clear advantage. Selling at vest may simplify tax management, since the position does not grow further and the shares sold at vesting generally create little or no additional capital gain, because the sale price is close to the value already taxed as income. It also means giving up any further participation in that stock’s performance, for better or worse.

Holding keeps you invested in the company and may align with a view that the stock has room to grow, but it also means each new vest adds further to a position that may already be concentrated in a single employer. There is no strategy here that applies universally. The choice generally depends on your existing concentration, your tax situation, and your own view of the company, and is worth weighing deliberately rather than defaulting into either path.

RSUs rarely arrive alone. Medtech executives often also hold incentive stock options (ISOs), non-qualified stock options (NSOs), or shares purchased through an employee stock purchase plan (ESPP), each with its own tax treatment and its own deadlines. ISOs can trigger alternative minimum tax in the year of exercise even if no shares are sold. NSOs create ordinary income at exercise. ESPP shares carry qualifying and disqualifying disposition rules that depend on how long they are held after purchase.

Treating each grant type as a separate, isolated decision may mean missing opportunities to manage the combined tax bill. For example, timing an option exercise in a year with a smaller RSU vest, rather than stacking both into the same year, could help manage which tax bracket the combined income lands in, though whether that timing is available or advisable depends on individual vesting schedules, expiration dates, and other income.

Coordinating vest and exercise timing across all of these grant types, rather than reacting to each one as it arrives, is generally the more structural version of this planning. Our equity compensation planning work starts from that same coordination across grant types rather than treating any single vest in isolation.